Novartis AG (NYSE:NVS) – Jefferies Group lowered their FY2017 earnings estimates for shares of Novartis AG in a note issued to investors on Thursday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings per share of $4.70 for the year, down from their previous estimate of $4.74. Jefferies Group also issued estimates for Novartis AG’s FY2018 earnings at $5.24 EPS, FY2019 earnings at $6.01 EPS, FY2020 earnings at $6.81 EPS and FY2021 earnings at $7.79 EPS.
Other equities research analysts also recently issued reports about the company. TheStreet upgraded Novartis AG from a “c+” rating to a “b” rating in a research report on Friday, June 2nd. Vetr downgraded Novartis AG from a “strong-buy” rating to a “buy” rating and set a $78.32 target price on the stock. in a research report on Thursday, April 6th. Barclays PLC upgraded Novartis AG from an “underweight” rating to an “equal weight” rating in a research report on Thursday, June 22nd. Zacks Investment Research upgraded Novartis AG from a “strong sell” rating to a “hold” rating in a research report on Monday, May 1st. Finally, Cowen and Company downgraded Novartis AG from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $87.00 to $77.00 in a research report on Wednesday, April 5th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company. Novartis AG currently has a consensus rating of “Hold” and a consensus target price of $82.99.
TRADEMARK VIOLATION NOTICE: “Jefferies Group Brokers Lower Earnings Estimates for Novartis AG (NYSE:NVS)” was originally reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.wkrb13.com/markets/2284292/jefferies-group-brokers-lower-earnings-estimates-for-novartis-ag-nysenvs.html.
Shares of Novartis AG (NYSE:NVS) opened at 82.32 on Monday. The company has a market capitalization of $194.74 billion, a price-to-earnings ratio of 30.95 and a beta of 0.73. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The stock has a 50 day moving average price of $81.82 and a 200-day moving average price of $76.18.
Novartis AG (NYSE:NVS) last posted its quarterly earnings results on Tuesday, April 25th. The company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. The business had revenue of $11.54 billion for the quarter, compared to analyst estimates of $11.59 billion. Novartis AG had a return on equity of 15.46% and a net margin of 13.10%. Novartis AG’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the company earned $1.17 EPS.
In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the firm’s stock in a transaction on Wednesday, July 5th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.01% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Howe & Rusling Inc. boosted its position in Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares in the last quarter. TCI Wealth Advisors Inc. boosted its position in Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares in the last quarter. Archford Capital Strategies LLC boosted its position in Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after buying an additional 621 shares in the last quarter. Kernodle & Katon Asset Management Group LLC boosted its position in Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares in the last quarter. Finally, North Star Investment Management Corp. boosted its position in Novartis AG by 50.3% in the first quarter. North Star Investment Management Corp. now owns 1,526 shares of the company’s stock worth $113,000 after buying an additional 511 shares in the last quarter. 11.29% of the stock is currently owned by hedge funds and other institutional investors.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284292/jefferies-group-brokers-lower-earnings-estimates-for-novartis-ag-nysenvs.html
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.